NASDAQ:HSGX - Histogenics Stock Price, Forecast & News

$0.34

-0.01 (-2.86 %)

(As of 12/16/2019 06:00 AM ET)

Add

Compare

Today's Range

$0.34

Now: $0.34▼

$0.36

50-Day Range

$0.26

MA: $0.30▼

$0.44

52-Week Range

$0.08

Now: $0.34▼

$1.43

Volume2.66 million shs

Average Volume10.71 million shs

Market Capitalization$32.16 million

P/E RatioN/A

Dividend YieldN/A

Beta3.1

Histogenics Corporation develops restorative cell therapies that would offer rapid-onset pain relief and restored function. The company was founded in 2000 and is headquartered in Waltham, Massachusetts.

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Surgical appliances & supplies

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:HSGX

Previous Symbol

CUSIPN/A

CIK1372299

Webhttp://www.histogenics.com/

Phone781-547-7900

Debt

Debt-to-Equity RatioN/A

Current Ratio4.05

Quick Ratio4.05

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value($0.01) per share

Price / Book-34.00

Profitability

EPS (Most Recent Fiscal Year)($0.79)

Net Income$-8,640,000.00

Net MarginsN/A

Return on Equity-34.96%

Return on Assets18.40%

Miscellaneous

Employees49

Outstanding Shares94,600,000

Market Cap$32.16 million

Next Earnings DateN/A

OptionableNot Optionable

Receive HSGX News and Ratings via Email

Sign-up to receive the latest news and ratings for HSGX and its competitors with MarketBeat's FREE daily newsletter.

Histogenics (NASDAQ:HSGX) Frequently Asked Questions

What is Histogenics' stock symbol?

Histogenics trades on the NASDAQ under the ticker symbol "HSGX."

How were Histogenics' earnings last quarter?

Histogenics Corp (NASDAQ:HSGX) posted its earnings results on Thursday, August, 9th. The biotechnology company reported ($0.13) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.23) by $0.10. View Histogenics' Earnings History.

What is the consensus analysts' recommendation for Histogenics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Histogenics in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Histogenics.

What are Wall Street analysts saying about Histogenics stock?

Here are some recent quotes from research analysts about Histogenics stock:

1. According to Zacks Investment Research, "Histogenics Corporation is a regenerative medicine company. It is focused on developing and commercializing products in the musculoskeletal segment. The company is developing NeoCart(R) product to provide treatment in the orthopedic space. Histogenics Corporation is headquartered in Waltham, Massachusetts. " (1/15/2019)
2. HC Wainwright analysts commented, "Valuation and risks to our investment thesis. Our price target of $21/share is based on an equally-weighted composite of: (a) $12.6/share, as a 35x multiple of taxed and diluted $3.85 discounted back to FY19 at 20% (in line with the expected PE multiple and discount rate of an early development-stage biotechnology company); and (b) an NPV of $29.3/ share (discounted cash flow analysis using a 12% discount rate and 3.5% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company). Translate Bio, Inc." (12/24/2018)

Has Histogenics been receiving favorable news coverage?

Headlines about HSGX stock have trended negative recently, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Histogenics earned a news sentiment score of -2.8 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Histogenics.

Who are some of Histogenics' key competitors?

Some companies that are related to Histogenics include ConforMIS (CFMS), Lakeland Industries (LAKE), COLLPLANT HOLDI/S (CLGN), Rewalk Robotics (RWLK), NanoVibronix (NAOV), Precision Therapeutics (POAI), Bionik Laboratories (BNKL), Ocugen (OCGN), Allied Healthcare Products (AHPI) and Avitar (AVTI).

What other stocks do shareholders of Histogenics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Histogenics investors own include Interpace Diagnostics Group (IDXG), Verastem (VSTM), Novavax (NVAX), Progenics Pharmaceuticals (PGNX), SCYNEXIS (SCYX), Magnegas Applied Tchnlgy Sltns (MNGA), Ocular Therapeutix (OCUL), Trevena (TRVN), Synergy Pharmaceuticals (SGYP) and Opko Health (OPK).

Who are Histogenics' key executives?

Histogenics' management team includes the folowing people:

Mr. Adam D. Gridley, Interim Pres, CEO Treasurer, Sec., Consultant & Director (Age 47)
Mr. Jonathan I. Lieber, Interim Chief Financial Officer (Age 49)
Mr. Stephen R. Kennedy, Consultant (Age 62)

When did Histogenics IPO?

(HSGX) raised $60 million in an initial public offering on Wednesday, December 3rd 2014. The company issued 4,300,000 shares at $13.00-$15.00 per share. Cowen and Company, Needham & Company and Canaccord Genuity served as the underwriters for the IPO and BTIG was co-manager.

How do I buy shares of Histogenics?

Shares of HSGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Histogenics' stock price today?

One share of HSGX stock can currently be purchased for approximately $0.34.

How big of a company is Histogenics?

Histogenics has a market capitalization of $32.16 million. The biotechnology company earns $-8,640,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis. Histogenics employs 49 workers across the globe.View Additional Information About Histogenics.

What is Histogenics' official website?

The official website for Histogenics is http://www.histogenics.com/.

How can I contact Histogenics?

Histogenics' mailing address is 830 WINTER STREET 3RD FLOOR, WALTHAM MA, 02451. The biotechnology company can be reached via phone at 781-547-7900 or via email at [email protected]

MarketBeat Community Rating for Histogenics (NASDAQ HSGX)

Community Ranking:		2.8 out of 5 ( )
Outperform Votes:		339 (Vote Outperform)
Underperform Votes:		266 (Vote Underperform)
Total Votes:		605

MarketBeat's community ratings are surveys of what our community members think about Histogenics and other stocks. Vote "Outperform" if you believe HSGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HSGX will underperform the S&P 500 over the long term. You may vote once every thirty days.

This page was last updated on 12/16/2019 by MarketBeat.com Staff

Featured Article: Leveraged Buyout (LBO) Explained